GUJTHEM — Gujarat Themis Biosyn Share Price
0.000.00%
Last trade - 00:00- IN₹30.74bn
- IN₹30.60bn
- IN₹1.70bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.81 | ||
| Price to Tang. Book | 13.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.94 | ||
| EV to EBITDA | 41.8 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 30.07% | ||
| Return on Equity | 26.24% | ||
| Operating Margin | 44.19% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 851.24 | 905.63 | 1,148.54 | 1,489.73 | 1,698.22 | n/a | n/a | 32.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +269.4 | +27.48 | +44.55 | +32.88 | +2.06 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through pharmaceuticals segment. Its product portfolio comprises Rifamycin-S and Lovastatin. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy).
Directors
- Dinesh Patel NEC (73)
- Jagadish Kaujalgi CEO
- Bharat Desai CFO
- Rdhul Soni CCO
- Sachin Patel NED (46)
- Siddharth Kusumgar IND
- Kirdndeep Mddon IND
- Vikram Sanghvi IND
- Vijay Agarwal NID (62)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 11th, 1981
- Public Since
- July 13th, 1993
- No. of Shareholders
- 30,094
- No. of Employees
- 160
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 108,965,265
- Address
- Plot No 69/6, MUMBAI, 400104
- Web
- https://www.gtbl.in/
- Phone
- +91 2267607080
- Auditors
- GMJ & Co.
Upcoming Events for GUJTHEM
Gujarat Themis Biosyn Ltd Annual Shareholders Meeting
Q1 2026 Gujarat Themis Biosyn Ltd Earnings Release
Q2 2026 Gujarat Themis Biosyn Ltd Earnings Release
Similar to GUJTHEM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Gujarat Themis Biosyn share price?
As of Today at 20:59 UTC, shares in Gujarat Themis Biosyn are trading at IN₹283.20. This share price information is delayed by 15 minutes.
How has the Gujarat Themis Biosyn share price performed this year?
Shares in Gujarat Themis Biosyn last closed at IN₹283.20 and the price had moved by over the past 365 days. In terms of relative price strength the Gujarat Themis Biosyn share price has matched the S&P BSE 100 Index by over the past year.
What are the analyst and broker recommendations for Gujarat Themis Biosyn?
There is no consensus recommendation for this security.
Find out moreWhat is the Gujarat Themis Biosyn dividend yield?
The Gujarat Themis Biosyn dividend yield is 0.06% based on the trailing twelve month period.
Does Gujarat Themis Biosyn pay a dividend?
Last year, Gujarat Themis Biosyn paid a total dividend of IN₹0.17, and it currently has a trailing dividend yield of 0.06%. We do not have any data on when Gujarat Themis Biosyn is to next pay dividends.
When does Gujarat Themis Biosyn next pay dividends?
We do not have data on when Gujarat Themis Biosyn is to next pay dividends. The historic dividend yield on Gujarat Themis Biosyn shares is currently 0.06%.
How do I buy Gujarat Themis Biosyn shares?
To buy shares in Gujarat Themis Biosyn you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gujarat Themis Biosyn?
As of the previous close price of IN₹283.20, shares in Gujarat Themis Biosyn had a market capitalisation of IN₹30.74bn.
Where are Gujarat Themis Biosyn shares listed?
Here are the trading details for Gujarat Themis Biosyn:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: GUJTHEM
What kind of share is Gujarat Themis Biosyn?
Based on an overall assessment of its quality, value and momentum Gujarat Themis Biosyn is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gujarat Themis Biosyn share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Gujarat Themis Biosyn share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gujarat Themis Biosyn. Over the past six months, its share price has matched the S&P BSE 100 Index by .
As of the last closing price of IN₹283.20, shares in Gujarat Themis Biosyn were trading +5.68% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gujarat Themis Biosyn PE Ratio?
The Gujarat Themis Biosyn PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹283.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gujarat Themis Biosyn?
Gujarat Themis Biosyn's management team is headed by:
- Dinesh Patel - NEC
- Jagadish Kaujalgi - CEO
- Bharat Desai - CFO
- Rdhul Soni - CCO
- Sachin Patel - NED
- Siddharth Kusumgar - IND
- Kirdndeep Mddon - IND
- Vikram Sanghvi - IND
- Vijay Agarwal - NID